P19 Hepatitis C viral infection and other risk factors for B-cell non-Hodgkin’s lymphoma in adult Egyptians – Withdrawn  by unknown
months. Patients were considered to be cured when stimulated Ct
was undetectable. Age, gender, tumour size, neck lymph-node
metastasis, TNM stage, extent of surgical resection, postoperative
external-beam radiation, and postoperative chemotherapy were
analysed in all patients.
Findings: Of 132 MTC patients who had locally curative surgery,
68 (51.5%) had a tumour larger than 4 cm. 92 patients (69.7%) were
biochemically cured and 76 (57.6%) cases involved lymph-node
metastasis. Biochemical cure was significantly correlated with
extrathyroid extension (p < 0.005), tumour size (p < 0.005), and
lymph-node metastases (p < 0.0001). The 5-year and 10-year can-
cer-specific cumulative survival rates were 73.4% and 19.6%,
respectively. In univariate analysis, age and the presence of node
metastases were significant prognostic factors. Only age
remained an independent prognostic factor in multivariate
analysis.
Interpretation: Clinical outcome is significantly better for MTC
patients younger than 45 years, regardless of tumour size and
node metastases. The younger age at diagnosis and modified rad-
ical neck dissection might enhance the outcome. Age was a
unique independent prognostic factor. Patients with MTC should
be regarded as having systemic disease; and patients with a
tumour larger than 4.0 cm, bilateral neck node metastases, and
accompanying systemic symptoms are unlikely to be biochemi-
cally cured, even with extensive surgery.
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P18 ECONOMIC EVALUATION OF ADJUVANT TRASTUZUMAB IN
THE TREATMENT OF EARLY, HER2/NEU-OVEREXPRESSING
BREAST CANCER IN SINGAPORE
G. De Lima Lopes. Johns Hopkins Singapore International Medical
Centre, Republic of Singapore. Johns Hopkins University School of
Medicine, Baltimore, MD, USA
Background: Trastuzumab has revolutionised the way we treat
early, HER2/neu-positive breast cancer, because it significantly
improves disease-free and overall survival. Little is known about
the societal costs and benefits of treatment with trastuzumab in
the adjuvant setting in Asia. This study aimed to be the first eco-
nomic evaluation of trastuzumab in Singapore and Asia, assess-
ing its net economic gains to society.
Methods: An analytic model was used to estimate societal costs
(and benefits) of treatment with trastuzumab in Singapore. Direct
costs were derived from actual patient costs at four treatment
centres in Singapore – two private and two public centres, com-
prising 60–70% of all patients with cancer. Indirect costs were
assessed as the loss of productivity caused by the disease or treat-
ment. Benefits to society were based on extra years of productiv-
ity (measured by GNI per capita) resulting from the quality-
adjusted life-years (QALY) saved with the use of trastuzumab, as
determined in the models by Kurian (J Clin Oncol 2007), Liberato
(J Clin Oncol 2007), and Garrison (Cancer 2007). Sensitivity analysis
was performed.
Findings: Incremental costs in Singapore were $26,971.05 (all
costs are in 2005 US dollars). The average cost per QALY was
$19,174.59 (median $18,993.70). Costs (benefits) to society ranged
from a cost of $79.42 to a benefit of $9,263.06 per person, depend-
ing on the model used (average benefit $4,375.89, median
$3,944.03). Sensitivity analysis ranged from a cost of $10,685.00
to a benefit of $17,298.79.
Interpretation: Treatment with adjuvant trastuzumab is likely
to generate net societal economic benefits in Singapore. Never-
theless, the lower range of possible outcomes does not refute
the possibility that treatment may actually generate costs; how-
ever, these costs fall within the range of acceptable cost-
effectiveness.
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P19 HEPATITIS C VIRAL INFECTION AND OTHER RISK FACTORS
FOR B-CELL NON-HODGKINS LYMPHOMA IN ADULT EGYPTIANS
– WITHDRAWN
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P20 NATIONAL LIVER TISSUE BANK AND CLINICAL DATABASE
IN CHINA
Y. Yang, Y. Liu, M. Wei, Y. Wu, J. Gao, L. Liu, W. Zhou*, H. Wang *,
M. Wu. Eastern Hepatobiliary Surgery Hospital, Second Military
Medical University, Shanghai, China
Background: To develop standardised and well-rounded mate-
rial for hepatology research.
Methods: The National Liver Tissue Bank (NLTB) project began
in China in 2008, to make well-characterised and optimally pre-
served liver tumour tissue available and to create a clinical
database.
Findings: From December, 2008, to June, 2010, more than 3000
individuals enrolled at the NLTB as liver tumour donors, includ-
ing 2317 cases of newly diagnosed hepatocellular carcinoma
(HCC), and about 1000 cases diagnosed as benign or malignant
liver tumours. The clinical database and sample store can be
managed easily and correctly with the data management plat-
form used.
Interpretation: We believe that the high-quality samples and
database with detailed information will become the cornerstone
of hepatology research, particularly in studies of diagnosis and
new treatments for HCC and other liver disease.
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